Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
SGLT2 inhibition reduces serum uric acid in patients with CKD, with larger effects at higher eGFR and in the absence of diabetes. However, the effect on uric acid is modest and did not translate into reduced risk of gout in EMPA-KIDNEY.
Authors
- Parminder K. Judge (ORCID: https://orcid.org/0000-0002-0083-3649)
- Jennifer B. Green (ORCID: https://orcid.org/0000-0002-9967-5352)
- Natalie Staplin (ORCID: https://orcid.org/0000-0003-4482-4418)
- David Z.I. Cherney (ORCID: https://orcid.org/0000-0003-4164-0429)
- Colin Baigent (ORCID: https://orcid.org/0000-0003-4856-7420)
- Jonathan Emberson (ORCID: https://orcid.org/0000-0001-7792-9422)
- Christoph Wanner (ORCID: https://orcid.org/0000-0001-9507-5301)
- Kaitlin J. Mayne (ORCID: https://orcid.org/0000-0002-5695-0270)
- David Preiss (ORCID: https://orcid.org/0000-0002-4646-5060)
- Emily Sammons (ORCID: https://orcid.org/0000-0002-8647-0366)
- Doreen Zhu (ORCID: https://orcid.org/0000-0002-8470-8430)
- William Guy Herrington (ORCID: https://orcid.org/0000-0003-1172-8243)
- Martin Landray (ORCID: https://orcid.org/0000-0001-6646-827X)
- Roberto Pontremoli (ORCID: https://orcid.org/0000-0003-1238-872X)
- Sibylle J. Hauske (ORCID: https://orcid.org/0000-0003-3319-3710)
- Richard Haynes (ORCID: https://orcid.org/0000-0002-1179-0023)
- Adeera Levin
- Rebecca J. Sardell
Institutions
- Boehringer Ingelheim (Germany) (DE)
- University of British Columbia (CA)
- University of Toronto (CA)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University of Oxford (GB)
- Clinical Research Institute (US)
- Ospedale Policlinico San Martino (IT)
- Oxford University Hospitals NHS Trust (GB)
- University of Glasgow (GB)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1093/ndt/gfae203
- Citations
- 18
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 6.11
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Regeneron Pharmaceuticals
- Fresenius Medical Care North America
- National Institute for Health and Care Research
- British Heart Foundation
- University of Oxford
- European Society of Cardiology
- Novo Nordisk
- Astellas Pharma
- Medical Research Council